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Abstract
Background: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled the AR-regulated 
kinome to identify clinically relevant and druggable effectors of AR signaling.
Methods: Using genome-wide approaches, we interrogated all AR regulated kinases. Among these, choline kinase 
alpha (CHKA) expression was evaluated in benign (n = 195), prostatic intraepithelial neoplasia (PIN) (n = 153) and 
prostate cancer (PCa) lesions (n = 359). We interrogated how CHKA regulates AR signaling using biochemical assays and 
investigated androgen regulation of CHKA expression in men with PCa, both untreated (n = 20) and treated with an 
androgen biosynthesis inhibitor degarelix (n = 27). We studied the effect of CHKA inhibition on the PCa transcriptome 
using RNA sequencing and tested the effect of CHKA inhibition on cell growth, clonogenic survival and invasion. Tumor 
xenografts (n = 6 per group) were generated in mice using genetically engineered prostate cancer cells with inducible 
CHKA knockdown. Data were analyzed with χ2 tests, Cox regression analysis, and Kaplan-Meier methods. All statistical 
tests were two-sided.
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Results: CHKA expression was shown to be androgen regulated in cell lines, xenografts, and human tissue (log fold change 
from 6.75 to 6.59, P = .002) and was positively associated with tumor stage. CHKA binds directly to the ligand-binding 
domain (LBD) of AR, enhancing its stability. As such, CHKA is the first kinase identified as an AR chaperone. Inhibition of 
CHKA repressed the AR transcriptional program including pathways enriched for regulation of protein folding, decreased 
AR protein levels, and inhibited the growth of PCa cell lines, human PCa explants, and tumor xenografts.
Conclusions: CHKA can act as an AR chaperone, providing, to our knowledge, the first evidence for kinases as molecular 
chaperones, making CHKA both a marker of tumor progression and a potential therapeutic target for PCa.
Prostate cancer (PCa) is a major cause of cancer-related deaths 
worldwide (1). The androgen receptor (AR) is a ligand-inducible 
transcription factor of the nuclear hormone receptor superfam-
ily that plays a critical role in tumor initiation, growth, and pro-
gression of PCa (2,3). Hence, therapies targeting the AR signaling 
axis provide an effective first-line treatment for advanced PCa 
(4,5). As with many other cancer types, resistance to therapy 
occurs in PCa in the form of progression to advanced castration-
resistant prostate cancer (CRPC) (6,7) and is accompanied by 
reactivation or maintenance of AR signaling, which triggers a 
unique AR transcriptome (8). Multiple direct mechanisms can 
stimulate AR signaling in advanced PCa, including amplification, 
gain-of-function mutations in the AR gene/androgen signaling 
pathway (9), and constitutively active AR splice variants such as 
AR-V7 (10,11). Indirect mechanisms driving elevation of AR pro-
tein expression in PCa include the upregulation of heat shock 
proteins (HSPs) that act as chaperones for AR. HSPs interact with 
the LBD of AR and promote its stability, folding, and activation. 
Consistent with this, targeting of HSPs in preclinical models 
inhibits AR function and tumor growth (12,13). In addition, we 
and others have shown the importance of kinases in regulating 
AR function and PCa progression (14–16).
These diverse resistance mechanisms highlight the reli-
ance of PCa on the maintenance of AR signaling, which controls 
a number of cellular pathways including metabolic fuelling of 
tumor growth (17), progression through cell cycle checkpoints 
(18), promotion of metastatic phenotypes (19), and DNA dam-
age repair (20,21). Moreover, a well-established feature of AR 
signaling in PCa is the existence of multiple feedback and feed-
forward circuits that form a robust, self-reinforcing signaling 
network. An example of this is negative auto-regulation of AR 
transcription (22,23) and reciprocal feedback between AR and 
PI3K signaling, which results in sensitivity to dual targeting of 
both pathways (24). Identification of clinically relevant targets 
that regulate AR function, as well as the key downstream path-
ways, is critical for more effective treatment of PCa.
Methods
Cell Culture
Unless stated otherwise, all cell lines were verified by genetic 
profiling of polymorphic short tandem repeat (STR) loci as per 
ATCC standards. We used either AmpFISTR test or GenePrint10 
test (Promega, Madison, WI) and analyzed all data using 
GeneMapper v4.0 software. LNCaP, C4-2, VCaP, PC3, PNT1a, 
RWPE-1, DUCaP, 22Rυ1, and DU145 cells were obtained from 
commercial suppliers and grown in RPMI cell culture medium 
containing 10% fetal bovine serum (FBS) and 1% penicillin/strep-
tomycin in a humidified incubator at 37 ºC with 5% CO2.
R1-AD1 was a subline derived from the CWR-R1 cell line. The 
identity of R1-AD1 was authenticated by positivity for the H874Y 
point mutation in the AR LBD as determined by polymerase 
chain reaction (PCR) and Sanger sequencing, and negativity for 
copy number imbalances along the length of the AR gene was 
determined by multiple ligation-dependent probe amplification 
(MLPA) assay. The identity of R1-D567 was authenticated by PCR 
and Sanger sequencing of the signature break fusion junction 
generated by transcription activator-like effector endonuclease 
(TALEN)–based genome engineering.
Patient Selection and PCa TMA Construction
Prostate tissues were obtained from 359 patients with a 
median age of 64  years (range  =  46–74  years) who underwent 
radical prostatectomy between 1993 and 2003. Samples and 
clinico-pathological data were retrieved from the files of the 
Department of Pathology, Centro Hospitalar do Porto, Portugal, 
and tissue microarray blocks (TMAs) were prepared. Prior to TMA 
construction, haematoxylin and eosin (H&E)–stained tumor sec-
tions of each radical prostatectomy specimen were re-assessed 
using the modified Gleason and 2010 pTNM classification (25). 
Representative areas of adjacent non-neoplastic prostate tissue, 
PIN lesions, and PCa were selected from the peripheral zone 
where cancer develops. Three cores from each sample (2 mm in 
diameter, with 0.8 mm between core centers) were incorporated 
into paraffin-blocked TMAs, using a TMA workstation (TMA 
builder, Beecher Instruments Inc. Technology). Four micron sec-
tions were cut for immunohistochemistry (IHC), and an H&E-
stained section from each TMA block was reviewed to confirm 
the presence of morphologically representative areas of the 
original tissues. The work was approved by the Departamento 
de Ensino Formação e Investigação (DEFI) Ethics Committee of 
Centro Hospitalar do Porto (ref. no. 017/08, 010-DEFI/015-CES).
Generation of Tumor Xenografts
All experiments were carried out in compliance with the UK 
Animals (Scientific Procedures) Act 1986 under a project licence 
with the approval of the Cancer Research UK Cambridge Institute 
Animal Welfare and Ethical Review body. Xenografts were initi-
ated in NOD scid gamma mice (n = 6 per group) by subcutaneous 
injection of 1 million C4-2b-luciferase (C42b-Sh#1 and nontar-
geting shLuc C4-2b) cells in 100  µL (50:50 phosphate buffered 
saline/matrigel, BD Bioscience, San Jose, CA). Mice were given 
doxycycline in drinking water (0.5 mg/mL in 2% sucrose solu-
tion) while control mice received 2% sucrose solution. Tumor 
size was measured with callipers weekly and calculated using 
the formula volume = (π/6)/abc or (π/6)/abb (if only 2 diameters 
are available), and a, b, c are the orthogonal axis of the tumor. 
Tumors were also monitored weekly by luminescence imaging 
after intraperitoneal injection of 150 mg/kg d-luciferin (Caliper 
Life Sciences) using Xenogen Imaging Analysis software Living 
Image 3.0 (Caliper Life Sciences, Hopkinton, MA), and lumines-
cence was plotted as photons per second for graphic analysis of 
growth kinetics. Turbo red fluorescent protein (tRFP) emission 
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was recorded using Xenogen camera once after three weeks 
while luciferase expression was the measured weekly. Mice 
were culled at the completion of experiment or when tumors 
reached 10% of body weight.
Statistical Analysis
Chi square tests in R were used to look at the association of 
clinical variables with CHKA, all dichotomized. Survival analysis 
of the patient data was carried out using the survival package 
(26). Cox regression analysis of time to biochemical recurrence-
free survival was carried out. Proportionality of hazards was 
confirmed by plotting them. There were several missing values 
in the dataset, so analysis was done on a complete case basis 
(cases complete for survival and clinical information). The 
analysis was initially carried out using CHKA as a predictor 
value, subsequent models adjusted for each dichotomized clini-
cal variable individually to see what effect it had on the CHKA 
predictor.
Recursive partitioning (RP) using a conditional inference 
framework was used to find a significant cutoff for each input 
gene for predicting recurrence-free survival using a prostate 
cancer gene expression dataset with accompanying survival 
data from 79 patients (27). This was implemented using the ctree 
(28) function in the R (R Core Team, 2014). Kaplan-Meier survival 
curves and recursive partitioning plots were displayed for those 
genes that are predictive of recurrence-free survival, with P val-
ues of less than .05 (corrected for the testing of multiple cutoffs, 
but not genes). Further details are given in the Supplementary 
Methods (available online). All statistical tests were two-sided.
Supplementary Materials
Supplementary information includes experimental proce-
dures; Supplementary Table 4 (available online) contains all the 
genomic data used in the manuscript including GEO accessions 
or web links. The probe set used in each data is also specified. 
The RNA-seq data generated during this work has been submit-
ted to Gene Expression Omnibus and is available for viewing at 
the following link http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token = ytazouoixxedjal&acc=GSE63700.
Results
The AR Kinome Suggests CHKA as a Clinically 
Relevant Target
To identify a therapeutically relevant subset of AR targets, we 
defined the AR-regulated kinome by performing a cross-plat-
form analysis of an androgen-stimulated gene expression time 
course (17) and a high-throughput real-time PCR kinome array. 
We identified 49 androgen-regulated kinase genes (Figure 1A), 
of which 25 were upregulated and 24 were downregulated 
(Supplementary Table  1, available online). By integrating gene 
expression with our chromatin immuno-precipitation sequenc-
ing (ChIP-seq) datasets (17), we found AR binding sites at the 
genomic loci of 22 of the 25 androgen upregulated kinases 
and 8 of the 24 downregulated kinases, providing evidence for 
direct AR regulation of a subset of these genes (Supplementary 
Table 1 and Supplementary Figure 1B, available online). Clinical 
gene expression data revealed that many androgen-upregulated 
kinases were also upregulated in primary and metastatic PCa 
(Supplementary Figure 1C and 1D, available online). Importantly, 
we confirmed the in vivo androgen regulation of a subset of 
these genes in tumor tissues from chemically castrated PCa 
patients (n = 15) in contrast to untreated tumors (n = 19) from 
age/tumor grade-matched patients, finding that 18 of the 25 in 
vitro androgen-upregulated kinases were statistically downreg-
ulated in response to castration in men with PCa (t test P < .05) 
(Supplementary Figures 1, E, and 6, A and B, available online).
Among these kinases several have previously been impli-
cated in PCa, including CAMKK2 (17) and IGF-1R (29). Protein 
interaction network and pathway analysis highlighted clusters 
of functional enrichment including growth factor receptors, 
MAPK, TGFβ, and metabolic signaling (Supplementary Figure 1F, 
available online). These datasets indicated that the CHKA gene 
could be a clinically relevant AR target gene. Supporting this 
idea, the CHKA has strong intragenic AR binding sites in PCa cell 
lines and in PCa tissue (Figure 1B and Supplementary Figure 2, 
A and B, available online). CHKA mRNA was statistically signifi-
cantly overexpressed in localized (primary) and metastatic PCa 
(30,31) (Figure 1, C and D) and was androgen-regulated in PCa cell 
lines (Supplementary Figure 2, C-E, available online). Of greater 
biological relevance, CHKA expression was decreased in tissues 
from patients treated with the LHRH analogue degarelix, both 
at the transcript (log fold change from 6.75 to 6.59, P = .002) and 
protein level compared with control patients without androgen 
deprivation (P  =  .006) (Figure  1, E and F). This, in combination 
with the known importance of phospho-choline alterations in 
PCa, prompted us to investigate the importance of CHKA.
CHKA protein expression was frequently increased in PCa 
(12% positive cases in non-neoplastic [NN] benign prostate 
compared with 36% positive cases in PCa; P < .001) (Figure 1G; 
Supplementary Figure  2F, available online) and showed some 
evidence of association with Gleason grade (≤ vs 7) and tumor 
stage (pT2 vs pT3). There was no evidence of an association 
of CHKA expression with age, PSA, or biochemical recurrence 
(Table  1; Supplementary Table  2, available online). However, 
CHKA was an independent predictor of biochemical recur-
rence-free survival when other clinical variables were included 
(Table  2; Supplementary Table  2, and see Supplementary 
Methods for details, available online), a finding supported by 
Kaplan-Meier analysis of a separate cohort of clinical samples 
(CHKA> 9.15, n = 15; CHKA ≤ 9.15, n = 64, P =  .017) (Figure 1H). 
Together, these results highlighted that CHKA potentially is a 
direct AR-regulated gene in vivo whose overexpression is prog-
nostic in PCa.
CHKA is a Eukaryotic Kinase That Acts as a Protein 
Chaperone
To test whether CHKA influences androgen signaling, we inves-
tigated whether CHKA interacts with the AR. Both CHKA iso-
forms (32) coprecipitated with the AR (Figure 2A). Interestingly, 
the CHKA2 isoform showed a stronger but transient interac-
tion, which decreased within 5 to 15 min of androgen treatment 
(Figure 2A), consistent with the timing of AR release from cyto-
plasmic chaperones and its translocation to the nucleus (33). 
The interaction was regained after 24 hours of androgen treat-
ment, consistent with AR localization returning to a steady state 
and with androgen-induced expression of CHKA protein at this 
time point (Supplementary Figure 2C, available online). Evidence 
of an interaction between the AR and CHKA was also observed 
in a reciprocal co-immunoprecipitation (CoIP) assay (pulling 
down CHKA and western blotting for the AR) (Supplementary 
Figure  2G, available online). Fluorescence microscopy imaging 
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Figure 1. Identification of choline kinase alpha (CHKA) as a clinically relevant androgen receptor (AR) target in prostate cancer (PCa). A) Gene expression time course 
heatmap showing androgen regulation of kinases in LNCaP cells treated with 1 nM R1881 androgen. Kinases identified as androgen-regulated on both Illumina bead-
arrays and SYBR Openarray Human Kinome panel are shown (values represent median centred Illumina beadarray). Blue color designates lower expression, and red 
indicates higher expression. B) Chromatin immuno-precipitation sequencing analyses from multiple studies on castration-resistant prostate cancer tissue and andro-
gen (R1881)-stimulated PCa cell lines (8, 17, 62, 63) illustrating intron-2 of the genomic locus of the CHKA gene and AR binding sites (coordinates reference GRCh38). 
C-D) Boxplots show CHKA transcript expression in benign tissue, primary PCa, and metastatic PCa in two independent gene expression datasets (30,31). Boxplots show 
interquartile range (IQR), 95% confidence interval (CI), and outlier points. E) Boxplot showing CHKA transcript levels in tumors from PCa patients treated with the lute-
inizing hormone-releasing hormone analogue degarelix, compared with tissue from untreated control PCa patients of matched disease stage. Boxplots show IQR, 95% 
CI, and outlier points. F) Immuno-histochemical staining intensity score of CHKA protein expression in the benign adjacent epithelia (in duplicates) and the prostate 
tumors (in triplicates) of men seven days after treatment or no treatment with degarelix; P = .006 two-sided Wilcox rank-sum test of IHC intensity. Representative 
images inset above. Scale bar = 100 µm. G) Bar plots showing prevalence of CHKA human staining in non-neoplastic (NN; 195 case patients), prostate intraepithelial 
neoplasia (PIN; 153 case patients), and tumor tissue (TT; 359 case patients) as a percentage of total case patients. Representative images inset below. Scale bar =100 µm. 
H) Kaplan-Meier survival curve from recursive partitioning analysis showing that high CHKA transcript levels are associated with poor recurrence-free survival in the 
Glinsky cohort (P = .017) (27). AR = androgen receptor; CHKA = choline kinase alpha; CI = confidence interval; CRPC = castration-resistant prostate cancer; IQR = inter-
quartile range; LHRH = luteinizing hormone-releasing hormone; R = R1881.
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of m-Cherry tagged CHKA (red) and green fluorescent protein 
tagged AR (GFP-AR; green) revealed evidence of colocalization 
between CHKA and the AR both in the cytosol and nucleus 
(Figure 2B; Supplementary Table 2, available online). Surprisingly, 
AR protein levels were reduced not only by AR knockdown but 
also by CHKA knockdown using either siRNA (Figure  2C) or a 
panel of inducible shRNAs (Figure  2D), indicating a reciprocal 
role of CHKA in regulating AR protein levels.
To determine whether the interaction between the AR and 
CHKA was direct or indirect, we screened several AR domain 
constructs (Figure  2E). Using a pull-down assay, we mapped a 
direct physical interaction between recombinant CHKA2 and 
the LBD of AR (ARLBD) (Figure 2F). Notably, this is the AR domain 
that interacts with HSPs that stabilize AR (34). We therefore 
asked whether CHKA could also stabilize AR conformation 
in protease protection assays using an ARDBD-LBD polypeptide 
expressed by bacterial cells grown in the presence or absence 
of androgen dihydrotertosterone (DHT) and with subsequent 
incubation ± DHT with a recombinant CHKA2. In the presence 
of both DHT and CHKA protein, there was reduced cleavage of 
the ARDBD-LBD polypeptide at both low and high concentrations of 
trypsin (Figure 2G, arrows 1a & 1b), as well as increased resist-
ance to cleavage of 21 and 35 kDa fragments, particularly at 
higher trypsin concentrations (Figure 2G, arrows 2 & 4). Control 
experiments using glutathione-S-transferase (GST) suggested a 
specific protection of the full-length ARDBD-LBD in the presence of 
CHKA but not GST (Figure 2H, arrows 1a & 1b). Similarly, there 
was a reduced cleavage of AR polypeptide fragments in the pres-
ence of CHKA (Figure 2H, arrows 2 & 4). We found that ARDBD-LBD  
expressed in the absence of DHT was extremely sensitive to 
complete trypsin digestion (Supplementary Figure 2H, available 
online) and this could be reversed by the addition of both DHT 
and CHKA, although not by DHT or CHKA individually. Together 
these data suggest that CHKA exerts a chaperone function on 
the AR.
We tested whether CHKA binding stabilized AR via binding 
to the ARLBD using R1-D567 cells that exclusively express an AR 
variant (ARv567es) lacking the LBD (10). This variant is constitu-
tively active and promotes prostate carcinogenesis (35), and its 
expression is associated with resistance to enzalutamide and 
abiraterone (11). While CHKA knockdown did not alter ARv567es 
expression in R1-D567 cells (Figure 2I), it decreased expression 
of DHT-stabilized full-length AR in isogenic R1-AD1 cells. These 
findings validate biochemical data and support a model in PCa 
whereby a chaperone function of CHKA stabilizes the AR exclu-
sively via binding to the ARLBD.
Reliance of the AR Transcriptional Program on CHKA 
in PCa
To further investigate the functional consequences of CHKA on 
AR signaling, we used a reporter assay to assess AR transactiva-
tion capacity in C4-2 PCa cells and observed a 2.5-fold decrease 
(P < .001) in R1881-induced AR transcriptional activity following 
CHKA knockdown using siCHKA (Figure 3A). CHKA knockdown 
decreased full-length AR transcriptional activity in R1-AD1 cells 
by 2-fold (P < .005) (Figure 3B) but failed to inhibit ARv567es vari-
ant (10) lacking the LBD in R1-D567 cells (Figure 3C), indicating 
that CHKA regulates AR transcriptional activity by binding to 
ARLBD, consistent with our biochemical data. As an additional 
approach to determine the role of CHKA in regulating AR signal-
ing, we used hexadecyl trimethylammonium bromide (referred 
Table 2. Final model from a backward Cox regression
Variable  
adjusted for Comparison No.* (events) HR (95% CI)
CHKA +ve vs –ve 228 (45) 1.88 (1.03 to 3.42)
Tumor stage pT3 vs pT2 228 (45) 2.18 (1.20 to 3.96)
* The number of case patients is the same to ensure comparability between 
models and is therefore all the case patients not missing survival and clinical 
information. The initial model included choline kinase alpha (CHKA), age, pros-
tate-specific antigen (PSA), Gleason stage, and tumor stage. Age was removed 
first followed by PSA and Gleason, leaving on CHKA and tumor stage in the 
model. CHKA = choline kinase alpha; CI = confidence interval; pT = tumor stage.
Table 1. χ2 square test results for association of dichotomized clinical-pathological data with CHKA (dichotomized, positive/negative)
Parameters Case patients No. (missing CHKA) Positive No. (%) Difference (95% CI)*
Age, y
 ≤64 252 (57) 68 (27.0) 1.3% (-9.2 to 11.8)
  >64
 Missing
222 (59)
006 (5)
59 (26.6)
1 (16.7)
PSA, ng/mL
 ≤5 099 (23) 28 (28.3) 1.7% (-12.7 to 15.3)
 >5
 Missing
269 (61)
112 (37)
73 (27.1)
27 (24.1)
Combined Gleason score
 ≤7 433 (108) 109 (25.2) 20.3% (-1.6 to 42.2)
 >7
 Missing
31 (5)
16 (8)
14 (45.1)
5 (31.3)
Tumor stage
 pT2 359 (92) 86 (24.0) 11.7% (-1.2 to 24.6)
 pT3
 Missing
98 (16)
23 (13)
36 (36.7)
6 (26.1)
Biochemical recurrence
 Absent 409 (105) 102 (24.9) 12.7% (-2.7 to 28.2)
 Present
 Missing
69 (15)
2 (1)
25 (36.2)
1 (50.0)
* Based on nonmissing CHKA values (n = 480). CHKA = choline kinase alpha; CI = confidence interval; PSA = prostate-specific antigen; pT = tumor stage.
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Figure 2. Choline kinase alpha (CHKA) as an androgen receptor (AR) chaperone. A) Co-immunoprecipitation showing interaction of endogenous AR and CHKA. LNCaP 
cell lysates were harvested at the indicated time points and incubated with the AR antibody followed by western blotting using the CHKA antibody. B) Fluorescence 
microscopy images showing intracellular colocalization of CHKA with AR. Images of HeLa cells cotransfected with mCherry-tagged CHKA (red) and green fluorescent 
protein-tagged AR T878A (green) and then treated with R1881 (1 nM) for two hours. Scale bar = 10 µm. C) Western blot showing the reduction of expression of CHKA 
and AR proteins in LNCaP cells transiently transfected with small interfering (si)-RNA targeting either AR (siAR) or CHKA (siCHKA) compared with nontargeting con-
trol siRNA (siNT); β-actin is the loading control. D) Western blot showing the reduction of expression of CHKA and AR proteins in C4-2b cells expressing two different 
CHKA small hairpin (sh)-RNAs (sh#1 and sh#2) and shRNA-targeting luciferase (shLuc) in a doxycycline inducible manner; β-actin is the loading control. E) Graphic 
representing several AR truncations employed in the glutathione-S-transferase (GST) pull-down experiment shown in (F). F) GST pull-down assay: GST alone and GST-
tagged domains of the AR were incubated with CHKA for two hours. CHKA was detected by immunoblotting with an anti-CHKA antibody. The intensity of the immune 
reactive bands was quantified using Image J and the fold interaction of each domain with CHKA, based on the intensity of the band calculated and plotted relative to 
GST = 1. Data show mean ± SD, *P < .05 (n = 5). G) Protease protection assay of ARDBD-LBD. His-tagged ARDBD-LBD was expressed in presence of dihydrotestosterone (DHT) 
and subjected to proteolytic digestion with 10 ng/μL or 100 ng/μ: trypsin ± pre-incubation with CHKA (2 picomoles) and ± DHT. Full-length AR polypeptide (band 1a) 
or proteolytic fragments (bands 1b, 2, 3, and 4) were then detected using an anti-AR C19 antibody. H) Protease protection assay of ARDBD-LBD. His-tagged ARDBD-LBD was 
expressed in presence of DHT and subjected to proteolytic digestion with 10 ng/μL trypsin ± pre-incubation with CHKA or GST (2 picomoles) and ± DHT. Full-length 
AR polypeptide (band 1a) or proteolytic fragments (bands 1b, 2, 3, and 4) were then detected using an anti-AR C19 antibody. I) Western blot of CHKA and AR in cells 
engineered to express full-length AR (R1-AD1 cells) and ARv567es (R1-D567 cells). Cells were transiently transfected with nontargeting (siNT) or siRNA targeting CHKA 
(siCHKA) and treated for 48 hours with vehicle or DHT; GAPDH is the loading control. AF = activation function; AR = androgen receptor; CHKA = choline kinase alpha; 
DAPI = 4’,6-diamidino-2-phenylindole; DBD = DNA-binding domain; DHT = dihydrotestosterone; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; GST = glu-
tathione-S-transferase; IP = immunoprecipitation; LBD = ligand-binding domain; NTD = amino terminal domain; sh = small hairpin RNA; si = small interfering RNA.
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Figure 3. Effect of choline kinase alpha (CHKA) on the androgen receptor (AR) transcription program. A) Luciferase reporter assay showing AR transactivation potential 
in C4-2 cells transiently transfected with MMTV-Luc and treated ± siCHKA and ± androgen (1 nM R1881) for 48 hours; bars show mean ± SD (n = 3). P value by two-sided 
Student’s t test. B-C) Luciferase reporter assay showing AR transactivation potential in R1-D567 and R1-AD1 cells transfected with PB3-Luc and treated ± siCHKA ± 
androgen (DHT, 10 nM); bars show mean ± SD (n = 3). D) Luciferase reporter assay of C4-2 cells transiently transfected with MMTV-Luc showing the dose response to 
CHKAi in cells treated with R1881 as indicated; bars show mean ± SD (n = 3). E) Bipartite interdomain N-C interaction based reporter assay in C4-2 cells. Cells were 
transiently transfected with MMTV-Luc ± pSVARN (ARN, AR N-terminus) and/or ± pSVARC1 (ARC, AR C-terminus) for 48 hours ± R1881 (1 nM) and ± CHKAi (1 μM); bars 
show ± SD (n = 3). F) Venn diagram showing the overlap between siCHKA-downregulated genes and androgen-upregulated genes and (G) Venn diagram showing the 
overlap between siCHKA-upregulated genes and androgen-downregulated genes. P values are Bonferroni-corrected hypergeometric tests (see below for details). Genes 
differentially expressed following CHKA siRNA knockdown were selected from biological triplicate experiments using a false discovery rate cutoff of .05. Androgen-
regulated genes were selected from an androgen treatment time course experiment in LNCaP cells, using autocorrelation values above background simulations to 
identify regulated genes. A core set of direct androgen-regulated genes was defined by taking such genes with AR binding site(s) within 25 kb. H) Barplots of -log2 
transformed P values comparing overlaps of up- and downregulated gene sets from siCHKA and AR-stimulated conditions. To assess the significance of the overlap 
between siCHKA and AR stimulation expression changes, we applied hypergeometric tests and resultant P values were adjusted for multiple testing using the Bonfer-
roni correction. I) Heatmap summary of functional annotations for overlapping AR- and CHKA-regulated genes: Enrichment of functional annotations for each gene set 
was calculated using the DAVID Gene Ontology tool, and Benjamini-adjusted P values are plotted. J) Gene set enrichment analysis (GSEA) plots of CHKA siRNA-ranked 
gene expression changes, highlighting AR-bound genes in cultured cell lines or in CRPC tumor tissue, which was regulated by androgen treatment in cultured cells 
or by castration in xenografts. K) Barplot summary of GSEA-normalized enrichment scores and FWER corrected P values for the CHKA siRNA gene expression profile 
compared with AR gene sets. Gene sets shown in (J-K) were from Sharma et al. (2013) and Mendiratta et al. (2009). L) Boxplots showing the expression values for three 
established AR-regulated genes following CHKA siRNA (siCHKA) transfection. Data show results of six biological replicates; boxplots show interquartile range, 95% 
confidence interval, and outlier points. * = P < .5; † = P < .01; ‡ = P < .001. CHKA = choline kinase alpha; CHKAi = choline kinase alpha inhibitor; FWER = family-wise error 
rate; CRPC = castration-resistant prostate cancer; GSEA = gene set enrichment analysis; MMTV = mouse mammary tumor virus; NT = nontargeting; RLU = relative light 
units; si = small interfering RNA.
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to as CHKAi), a structural analogue of choline that binds to 
CHKA and inhibits conversion of choline into phosphocholine 
(36), a metabolic reaction in the Kennedy pathway that is cata-
lyzed by CHKA. Like CHKA knockdown, CHKAi decreased andro-
gen-induced AR transcriptional activity in a dose-dependent 
manner from 122-fold (R1881 alone) to 34-fold (P < .001; R1881 
with 1 µM CHKAi) in C4-2 cells (Figure 3D). The level of inhibi-
tion was equivalent to that of the new-generation AR antago-
nist (enzalutamide) and statistically significantly greater than 
a first-generation AR antagonist bicalutamide (Supplementary 
Figure  3A, available online). Using a bipartite N-C AR reporter 
assay (37), we found that CHKAi abrogated the AR N-C interdo-
main interaction that is associated with agonist-induced tran-
scriptional activity and stability of the AR, consistent with a 
chaperone function of CHKA (Figure 3E). In line with this, CHKAi 
repressed CHKA and AR protein levels to a similar extent with 
CHKA knockdown (Supplementary Figure 3B, available online). 
CHKAi also decreased androgen-stimulated nuclear AR levels 
(Supplementary Figure. 3C, available online).
Transcriptome sequencing from CHKA knocked down C4-2 
cells highlighted the global impact of CHKA on the AR tran-
scriptome. We found a statistically significant bidirectional 
overlap between siCHKA and androgen-regulated genes (519 
genes, 58% of the androgen-upregulated transcriptome; 487 
genes 42% of the androgen-downregulated genes, hyper-
geometric P < .001) (Figure  3, F and G). Among the siCHKA-
downregulated genes, almost 50% showed evidence of direct 
AR regulation (AR binding within 25 kb) (Figure 3H), which is 
consistent with a global role for CHKA in AR-dependent tran-
scriptional regulation. Pathway analysis identified common 
cellular processes regulated by the AR and CHKA, includ-
ing enrichment of sterol metabolic processes, lipid biosyn-
thetic processes, cell redox homeostasis, and GTPase activity 
(Figure 3I). Most notably, the CHKA knockdown signature was 
enriched for pathways regulating protein folding and cellular 
protein localization, consistent with its chaperone function 
identified herein. An orthologous gene set enrichment anal-
ysis following CHKA knockdown revealed a statistically sig-
nificant enrichment of AR-bound, androgen-regulated genes 
identified in multiple datasets from cell lines and castration-
resistant prostate cancer (CRPC) (FWER P < .05) (Figure 3, J and 
K). We confirmed that archetypal AR target genes including 
KLK3 (PSA), TMPRSS2, and SLC45A3 were downregulated by 
CHKA knockdown (Figure  3L) and that the effects of CHKA 
depletion on endogenous AR targets only occurred in andro-
gen-stimulated conditions, indicating that these effects are AR 
dependent (Supplementary Figure 3D, available online). These 
analyses highlight a functional link between AR and CHKA 
signaling, consistent with our biochemical and reporter gene 
studies, indicating a cooperative function of CHKA in driv-
ing the AR-regulated transcriptome by stabilizing AR protein 
levels.
Effect of CHKA Inhibition on PCa Growth
Because of its vital role in the Kennedy pathway, all investi-
gated PCa cell lines express CHKA (Figure  4A), providing an 
opportunity to interrogate the effects of CHKA inhibition on 
androgen-induced cell growth. CHKA inhibition by siRNA-
mediated knockdown and also by CHKAi treatment effectively 
decreased the confluence of C4-2 cells in a manner similar to 
AR inhibition (Supplementary Figure 4A, available online). CHKA 
knockdown in LNCaP cells led to a dose-dependent reduction in 
androgen-stimulated growth in these AR-expressing cells (1.3- 
and 2.0-fold reduction, with 12.5 nM and 25 nM siCHKA, respec-
tively) (Figure  4B). In a panel of AR-positive PCa cells, CHKA 
knockdown caused inhibition of androgen-stimulated growth 
comparable with the effects of AR knockdown but had only a 
modest effect on the growth of AR-null PCa cells PC3 and DU145 
PCa cells and normal prostate epithelial PNT1a and RWPE-1 cells 
(Figure 4C; Supplementary Figure 4, B and C, available online). 
Similarly, CHKAi had profound growth inhibitory effects on 
AR-positive C4-2 and LNCaP-LN3 cells, which were partially 
reversed by the synthetic androgen R1881. CHKAi only modestly 
inhibited growth of PC3, DU145, and PNT1a cells (Figure  4D; 
Supplementary Figure 4, D and E, available online). These data 
are collectively consistent with a greater effect of CHKA on the 
growth of AR-expressing PCa cells, likely resulting from dual 
inhibition of AR signaling and the Kennedy pathway in these 
cells. In clonogenic survival assay with LNCaP cells, AR antago-
nists bicalutamide and enzalutamide decreased colony num-
ber by 1.5- (P < .001) and 2.3-fold (P < .001), respectively, while 
CHKAi reduced the clonogenic survival of androgen-dependent 
LNCaP by more than 50-fold (P < .001) (Figure 4E). Similar results 
were obtained for another androgen-dependent cell line DUCaP 
(Supplementary Figure 4F, available online). In androgen-inde-
pendent VCaP cells, bicalutamide was not effective at clonal 
repression while enzalutamide was marginally effective (1.3-
fold, P < .01); however, CHKAi treatment led to a 7-fold decrease 
in clonogenic potential (P < .01) (Figure 4E). Results with simi-
lar trends were obtained for androgen-independent LNCaP-LN3 
(Supplementary Figure  4G, available online). The growth-pro-
moting role of CHKA does not depend on the catalytic activity 
of CHKA because the addition of exogenous phosphocholine or 
phosphatidylcholine did not rescue growth inhibition by CHKAi 
(Supplementary Figure 4H, available online). In an ex vivo cul-
ture assay, treatment of hormone-naïve primary PCa tissue with 
bicalutamide and CHKAi decreased AR expression in tumor 
epithelia while both anti-androgens and CHKAi increased lev-
els of cleaved caspase-3, a marker of apoptosis (Figure  4G). 
Concordantly, CHKAi treatment increased the content of glycer-
ophosphocholine (Figure 4H), a metabolic marker of apoptosis. 
CHKAi also increased apoptosis, and this increase was reversed 
by androgen co-treatment (Supplementary Figure  4I, available 
online). Collectively, these experiments indicate that CHKA inhi-
bition opposes androgen action, thus triggering apoptosis in PCa 
cells and tissue.
Impact of CHKA Knockdown on Tumor Growth and 
Invasion
To understand the effect of perturbing CHKA function on tumor 
growth kinetics, we used the highly aggressive C4-2b luciferase 
cell line and engineered it to express three distinct CHKA shR-
NAs (sh#1, sh#2, and sh#3) in a doxycycline-inducible manner. 
In the presence of doxycycline, sh#1 did not robustly decrease 
CHKA levels, but the two other CHKA shRNAs (sh#2 & sh#3) were 
effective at decreasing CHKA levels (Figure 5A). These shRNAs 
particularly reduced levels of the CHKA2 isoform that had shown 
stronger interaction with AR (Figures 2A and 5A). Consistent with 
the decreased CHKA levels in cells expressing sh#2 and sh#3, we 
observed a reduced growth rate in both of these shRNA clones 
following doxycycline induction compared with either sh#1 or 
shLuc cells (Figure 5B). Xenograft tumors were generated with 
CHKA sh#2 cells, which upon treatment with doxycycline grew 
slower than shCHKA xenograft without doxycycline treatment 
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Figure 4. Effect of choline kinase alpha (CHKA) inhibition on prostate cancer (PCa) growth. A) Western blot showing CHKA expression in five PCa cell lines; β-actin is 
the loading control. B) MTS assay of LNCaP cells transfected with two concentrations of siNT or siCHKA. Cells were grown in the presence or absence of 1 nM R1881 for 
120 hours; bars show mean ± SD (n = 3). P values by two-sided Student’s t test. C) MTS assay in three transiently transfected PCa cell lines with 25 nM siNT, siCHKA, or 
si-androgen receptor (AR) in response to androgen R1881 (1 nM); bars show mean ± SD (n = 3). P values by two-sided Student’s t test. D) MTS viability assay showing cell 
viability in PCa cells treated with R1881 (1 nM), bicalutamide (1 µM), and CHKAi (1 µM) data show mean ± SD (n = 3). P values by two-sided Student’s t test. E-F) Clono-
genic cell survival assay in LNCaP (E) and VCaP (F) cell lines treated for 14 days with bicalutamide, enzalutamide, or CHKAi (all at 10 µM); bars show mean ± SD (n = 3). 
P values by two-sided Student’s t test. G) Upper panel; photo micrographs of PCa explants treated with the drugs indicated. Scale bar = 100 µm. Lower panel; barplot 
showing the percentage of nuclei positive for the expression of AR and CC3 in human PCa tissue cultured ex vivo and treated with enzalutamide, bicalutamide, or 
CHKAi (10 µM). H) Upper panel: scores plot from principal component analysis of 1H NMR metabolite profiles of LNCaP cells. Control (black dots) and CHKAi treated (red 
dots). Lower panel shows loadings plot from principal component analysis of 1H NMR metabolite profiles. * = P < .05; † = P < .01; ‡ = P < .001. AD = androgen-dependent; 
AI = androgen-independent; AR = androgen receptor; Bic = bicalutamide; CC3 = cleaved caspase 3; CHKA = choline kinase alpha; CHKAi = choline kinase alpha inhibitor; 
Ctrl = control; Enz = enzalutamide; nM = nanomolar; NMR = nuclear magnetic resonance; NT = nontargeting; Si = small interfering RNA.
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(week 3 and week 4, Mann-Whitney P < .05) (Figure  5C) and 
showed a reduced bioluminescent growth profile than in tumors 
in the nondoxycycline control group (week 4, Mann-Whitney P < 
.05) (Figure 5D). The doxycycline-mediated induction of shRNA 
was confirmed by the induction of turbo red fluorescent protein 
(Supplementary Figure  5A, available online). Further analysis 
of the excised tumor xenografts confirmed a tendency towards 
decreased CHKA levels and clearly decreased AR protein expres-
sion in CHKA sh#2 xenografts from mice treated with doxycy-
cline (Supplementary Figure 5, B and C, available online). CHKA 
activity can be considered to have conferred an invasive pheno-
type on PCa cells because both CHKA and AR depletion delayed 
“wound healing” in a scratch wound assay to a comparable 
extent (1.6-fold decrease as compared with siNT) (Figure 5E) and 
similarly decreased invasion in both a Matrigel invasion assay (P 
< .001) (Figure 5F) and a Boyden Chamber assay (Supplementary 
Figure 5D, available online). These observations are consistent 
with PCa cells requiring CHKA and the AR for motility, as sug-
gested by transcriptome analysis enrichment of pathways regu-
lating GTPase activity (Figure 3I).
The data presented here demonstrate the importance of 
CHKA inhibition in decreasing AR levels and repressing PCa 
growth and invasion, highlighting the potential future benefits 
of inhibitors of this kinase in the clinical management of PCa.
Figure 5. Effect of choline kinase alpha (CHKA) depletion on metastatic features and tumor progression. A) Western blot showing expression of CHKA in clones of 
C4-2b cells with dox-inducible small hairpin (sh)-RNA targeting CHKA (sh#1, sh#2, sh#3, or shLuc control) treated with doxycycline (1 μM) for 72 hours; β-actin is the 
loading control. B) Growth profiles for C4-2b cell clones (sh#1, sh#2, sh#3, and shLuc control) in response to doxycycline induction of the respective shRNAs; lines show 
mean (n = 6). Error bars represent SD. C-D) Boxplot showing progression of tumor xenografts of shLuc and shCHKA C4-2b cells measured over four weeks (n = 6 per 
group) by (C) callipers to determine the volume and (D) by Xenogen camera to measure bioluminescence. Significance was calculated by the Mann-Whitney U test. 
Boxplots show data spread, boxes show interquartile range, error bars show 95% confidence intervals, and data points show outlier values. E) Scratch wound assay 
with VCaP cells showing the time course of wound closure after transient transfection with the small interfering (si)-NT, si-androgen receptor (AR), or siCHKA; lines 
show ± SD (n = 4). F) Matrigel-based inverted invasion assay with GFP expressing C4-2 cells transiently transfected with the siRNAs shown; bars show means ± SD 
(n = 3), significance calculated by D’Agostino & Pearson omnibus normality test, P < .0001. * = P < .05; † = P < .0001. AR = androgen receptor; CHKA = choline kinase alpha; 
Dox = doxycycline; NT = nontargeting; sh = small hairpin; si = small interfering RNA.
11 of 13 | JNCI J Natl Cancer Inst, 2016, Vol. 108, No. 5
a
r
t
ic
le
a
r
t
ic
le
Discussion
By employing genome-wide approaches, we characterize the 
AR-regulated kinome in PCa and provide direct evidence that 
CHKA is a chaperone for AR, promoting its stability and func-
tion. Indeed, to our knowledge this is the first report indicating 
that kinases can act as chaperones. Decreasing CHKA protein 
levels, both by siRNA knockdown and CHKA inhibitor, antago-
nized AR signaling and constrained development of aggressive 
phenotypes in models of PCa. We propose that CHKA promotes 
AR signaling and that therapeutic targeting of CHKA has the 
potential to improve management of advanced PCa.
Initial profiling of the AR-regulated kinome in PCa revealed 
functionally and clinically important signaling events down-
stream of the AR in PCa. Within the AR-regulated kinome, we 
characterized CHKA as a chaperone that regulates AR signal-
ing, elucidating a feed-forward AR-CHKA signaling loop that 
reinforces AR activity and allows CHKA to maintain its expres-
sion in PCa. We show that the chaperone function of CHKA 
confers a growth advantage on PCa by stabilizing the AR in 
addition to its well-known function in fuelling membrane pro-
duction through the Kennedy pathway (38) (Figure 6), suggest-
ing a de facto role for CHKA as a rate-limiting factor in cancer 
cell growth.
In advanced PCa models, AR knockdown is very effective 
in repressing tumor growth (39,40), but this has not yet been 
achieved long-term in the clinic. Recently, targeting the expres-
sion and/or activity of AR and its interacting networks using 
enzalutamide and abiraterone has established the paradigm of 
inhibiting the AR axis for the treatment of CRPC (4,5), provid-
ing impetus for the development of more effective inhibitors to 
target the AR axis (41,42). Unfortunately, resistance to these new 
therapies targeting AR signaling has begun to emerge, primarily 
involving amplification or gain-of-function point mutations and 
potentially splice variants in the AR gene (7,11). This indicates 
strong dependence of advanced PCa on continued AR signaling 
and provides a unique opportunity to target other facets of AR 
full-length signaling, including chaperones such as CHKA, to 
decrease AR levels.
The discovery that CHKA acts as a chaperone provides a 
potential explanation for an earlier study in breast cancer, which 
reported promotion of cancer cell growth by both wild-type and 
kinase-dead CHKA mutants, suggesting that the CHKA protein 
level per se, and not its catalytic function, is required for tumor 
cell growth (43). Another recent report on breast cancer cell 
growth comparing CHKA knockdown with catalytic inhibition 
by CHKA inhibitors also suggested that downregulation of CHKA 
protein levels, and not merely the catalytic activity, is required 
for cancer cell survival (44), further supporting the concept that 
CHKA may have a dual chaperone and kinase function in can-
cer. Indeed, independent of their catalytic function, kinases can 
regulate diverse cellular processes, including stimulation of 
DNA synthesis (45), allosteric effects on enzymes promoting cell 
survival (46), and the scaffolding of protein complexes (47). Our 
work therefore provides a conceptual advance in kinase biology 
by showing that a kinase can act as a chaperone, in this case for 
the AR, which may provide one explanation for the emergence 
of resistance to kinase inhibitors in a range of tumors where 
only the catalytic function of a kinase is targeted (48–50).
A number of studies have documented the overexpres-
sion of CHKA protein in multiple cancer types including 
breast, colorectal, endometrial, lung, ovarian, and prostate 
(51,52). Consistent with this, many solid tumors, includ-
ing PCa, exhibit an increased phosphatidylcholine:choline 
ratio in tumor foci (53). Therefore, CHKA is being pursued 
as a therapeutic target and prognostic marker in advanced 
disease for a range of tumor types (54–56). Indeed, a phase 1 
study of a CHKA inhibitor for the treatment of solid tumors 
has recently completed recruitment (ClinicalTrial.gov identi-
fier NCT01215864). Our work identifies a specific clinical niche 
for future phase I and II trials in PCa using CHKA inhibitors. 
This discovery also enhances the prospects for personalized 
Figure 6. Proposed model depicting classical and nonclassical functions of choline kinase alpha (CHKA). Classical model involves ubiquitination and activation of 
androgen receptor (AR)–dependent transcription, which results in upregulation of CHKA, which is required for the execution of the Kennedy pathway to produce phos-
phatidylcholine required for plasma membrane biogenesis. In addition to its role in Kennedy pathway, CHKA can also interact with the AR in cytoplasm and promotes 
its stability (nonclassical). This could lead to AR overexpression and increased AR signalling, which in turn may allow for more CHKA production. AR = androgen recep-
tor; CHKA = choline kinase alpha; mRNA = Messenger RNA.
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PCa therapy by stratifying patient cohorts according to their 
AR status. Majority of PCa express a full-length AR mutated 
in the LBD and/or have amplification of AR contributing to 
resistance to conventional ADT. These patients are more 
likely to benefit from therapeutic targeting of CHKA than the 
subset of patients expressing only AR variants such as AR-V7, 
which lacks the ARLBD and would be predicted to not interact 
with CHKA. Appropriate patient selection can avoid unneces-
sary overtreatment and toxicity.
CHKA contains multiple “NR” box or LxxLL motifs often 
found in coregulatory proteins of nuclear receptors. Because the 
LBD is highly conserved among members of the nuclear recep-
tor superfamily, it is likely that CHKA may function as a chap-
erone for other nuclear receptors. In view of the approximately 
76% sequence homology between the LBD of the glucocorticoid 
receptor (GR) and AR (57), and the antagonism of the GR by the 
AR antagonist cyproterone acetate (58), it is plausible that the 
chaperone function of CHKA may also stabilize GR and other 
members of the nuclear receptor superfamily. Thus, CHKA inhi-
bition could be an effective therapeutic approach in the treat-
ment of PCa, where AR function is bypassed by GR (59). Our 
study also provides a rationale for testing a CHKA inhibitor in 
60% to 70% cases of molecular apocrine-type breast cancers that 
rely on AR signaling (60,61).
This study also had some limitations. Firstly, the CHKAi 
employed in this study is a generic inhibitor and some of its 
effects on the cell growth may have been more pronounced 
as compared with the siRNA studies owing to the inhibition 
of other related kinases, although many experiments with the 
inhibitor and siRNA produced concordant results. This under-
scores the need for developing highly specific CHKA inhibi-
tors. Secondly, as CHKA protects AR by binding to its LBD, PCa 
patients whose tumors are driven by ARVs may still maintain AR 
signaling despite therapeutic targeting of CHKA. Moreover, the 
results we reported are underpinned by appropriate statistics, 
although in some of the functional studies the outcomes should 
be interpreted against the number of experiments and variance 
we reported.
The discovery of a chaperone function of CHKA for AR sign-
aling might also have wider implications in the treatment of 
other cancers and should accelerate the screening of potential 
CHKA inhibitors that will not only inhibit the catalytic function 
but also decrease the CHKA protein level. We believe our work 
will direct efforts in the treatment of PCa in particular, but also 
for other cancers, by stimulating a systematic re-evaluation of 
CHKA as a therapeutic target, especially in tumors where it is 
overexpressed and may exhibit chaperone-analogous effects on 
other oncogenic proteins.
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